Home > Insider Trading > Filing (0001209191-21-065616)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1678660	Prelude Therapeutics Inc	PRLD	Pharmaceutical Preparations (2834)	811384762

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1824625	Deborah Morosini	C/O Prelude Therapeutics Incorporated 200 Powder Mill Road Wilmington DE 19803	Evp, Chief Of Clinical Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-11-16	28,751	$12.85	29,195	No	4	M	Direct
Common Stock	Disposition	2021-11-16	28,351	$15.87	844	No	4	S	Direct
Common Stock	Disposition	2021-11-16	400	$16.43	444	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2021-11-16	28,751	$0.00	28,751	$12.85

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
196,045		2030-09-01	No	4	M	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.41 to $16.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.41 to $16.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The stock option vested as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.